Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

• Ferric carboxymaltose significantly improves hemoglobin levels compared to placebo in iron deficiency anemia. • FCM is non-inferior to other intravenous iron formulations and has a similar overall safety profile. • FCM is associated with fewer gastrointestinal adverse events than oral iron supplements. • The convenience of single-dose FCM administration may enhance patient compliance and healthcare efficiency.